Bispyridinium dienes: Histone deacetylase inhibitors with selective activities

Journal of Medicinal Chemistry

Volumn 50, Issue 10, 2007, Pages 2497-2505

  Pérez Balado, Carlos ^a   Nebbioso, Angela ^b   Rodríguez Graña, Paula ^a   Minichiello, Annunziata ^b   Miceli, Marco ^b   Altucci, Lucia ^b,c   De Lera, Ángel R ^a  

^a UNIVERSITY OF VIGO   (Spain)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (OCT 7 ENYL) 3 [12 [3 (PENT 4 ENYL)PYRIDINIUM 1 YL]DODECYL]PYRIDINIUM CHLORIDE IODIDE; 3 (HEX 5 ENYL) 1 [12 [1 (OCT 7 ENYL)PYRIDINIUM 3 YL]DODECYL]PYRIDINIUM CHLORIDE IODIDE; ALPHA TUBULIN; AMINE; BISPYRIDINIUM DIENE; CYCLOSTELLETTAMINE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE INHIBITOR; LYSINE; PROTEIN P21; PYRIDINIUM DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL STRAIN U937; CONTROLLED STUDY; DRUG ACETYLATION; ENZYMATIC ASSAY; HUMAN; HUMAN CELL; RING CLOSING METATHESIS; UPREGULATION;

ACETYLATION; ALKADIENES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HISTONE DEACETYLASES; HUMANS; MACROCYCLIC COMPOUNDS; PYRIDINIUM COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN;

EID: 34249081115     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070028m     Document Type: Article

References (53)

1. (a) Baylin, S. B.; Ohm, J. E. Epigenetic Gene Silencing in Cancer-A Mechanism for Early Oncogenic Pathway Addiction? Nature Rev. Cancer 2006, 6, 107-116.
2. (b) Yoo, C. B.; Jones, P. A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discovery 2006, 5, 37-50.
3. Marmorstein, R. Protein Modules that Manipulate Histone Tails for Chromatin Regulation. Nat. Rev. Mol. Cell Biol. 2001, 2, 422-432.
4. Biel, M.; Wascholowski, V.; Giannis, A. Epigenetics-An Epicenter of Gene Regulation: Histones and Histone-Modifying Enzymes. Angew. Chem., Int. Ed. 2005, 44, 3186-3216.
5. (a) Kouzarides, T. Acetylation: a regulatory modification to rival phosphorylation. EMBO J. 2000, 19, 1176-1179.
6. (b) Mai, A.; Massa, S.; Rotili, D.; Cerbara, I.; Valente, S.; Pezzi, R.; Simeoni, S.; Ragno, R. Histone Deacetylation in Epigenetics: An Attractive Target for Anticancer Therapy. Med. Res. Rev. 2005, 25, 261-309.
7. (a) Bannister, A. J.; Kouzarides, T. Reversing histone methylation. Nature 2005, 436, 1103-1106.
8. (b) Bedford, M. T.; Richard, S. Arginine Methylation: An Emerging Regulator of Protein Function. Cell 2005, 18, 263-272.
9. (c) Jenuwein, T. The epigenetic magic of histone lysine methylation. FEBS J. 2006, 273, 3121-3135.
10. (a) Das, P. M.; Singal, R. DNA methylation and cancer. J. Clin. Oncol. 2004, 22, 4632-4642.
11. (b) Schneider, J.; Shilatifard, A. Histone Demethylation by Hydroxylation: Chemistry in Action. ACS Chem. Biol. 2006, 1, 75-81.
12. (a) Minucci, S.; Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6, 38-51.
13. (b) Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discovery 2006, 5, 769-784.
14. Grozinger, C. M.; Schreiber, S. L. Deacetylase Enzymes: Biological Functions and the Use of Small Molecule Inhibitors. Chem. Biol. 2002, 9, 3-16.
15. (a) Nebbioso, A.; Clarke, N.; Bontempo, P.; Volz, E.; Alvarez, R.; Schiavone, E. M.; Weisz, A.; Bresciani, F.; de Lera, A. R.; Gronemeyer, H.; Altucci, L. Tumor-selective action of HDAC Inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 2005, 11, 77-84.
16. (b) Insinga, A.; Monestiroli, S.; Ronzoni, S.; Gelmetti, V.; Marchesi, F.; Viale, A.; Altucci, L.; Nervi, C.; Minucci, S.; Pelicci, P. G. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 2005, 11, 71-76.
17. (a) Fusetani, N.; Asai, N.; Matsunaga, S.; Honda, K.; Yasumuro, K. Bioactive marine metabolites. 59. Cyclostellettamines A-F, pyridine alkaloids which inhibit binding of methyl quinuclidinyl benzylate (QNB) to muscarinic acetylcholine receptors, from the marine sponge, Stelletta maxima. Tetrahedron Lett. 1994, 35, 3967-3970.
18. (b) Oku, N.; Nagai, K.; Shindoh, N.; Terada, Y.; Van Soest, R. W. M.; Matsunaga, S.; Fusetani, N. Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg. Med. Chem. Lett. 2004, 14, 2617-2620.
19. (c) De Oliveira, J. H. H. L.; Grube, A.; Koeck, M.; Berlinck, R. G. S.; Macedo, M. L.; Ferreira, A. G.; Hajdu, E. Ingenamine G and cyclostellettamines G-l, K, and L from the new Brazilian species of marine sponge Pachychalina sp. J. Nat. Prod. 2004, 67, 1687-1689.
20. Miller, T. A.; Witter, D. J.; Belvedere, S. Histone Deacetylase Inhibitors. J. Med. Chem. 2003, 46, 5097-5114.
21. (a) Anan, H.; Seki, N.; Noshiro, O.; Honda, K.; Yasumuro, K.; Ozasa, T.; Fusetani, N. Total synthesis of cyclostellettamine C, a bispyridinium macrocyclic alkaloid having muscarinic acetylcholine receptor antagonistic activity. Tetrahedron 1996, 52, 10849-10860.
22. (b) Baldwin, J. E.; Spring, D. R.; Atkinson, C. E.; Lee, V. Efficient synthesis of the sponge alkaloids cyclostellettamines A-F. Tetrahedron 1998, 54, 13655-13680.
23. (c) Grube, A.; Timm, C.; Koeck, M. Synthesis and mass spectrometric analysis of cyclostellettamines H, I, K and L. Eur. J. Org. Chem. 2006, 1285-1295.
24. Nicolaou, K. C.; Bulger, P. G.; Sarlah, D. Metathesis Reactions in Total Synthesis. Angew. Chem., Int. Ed. 2005, 44, 4490-4527.
25. Davies-Coleman, M. T.; Faulkner, D. J.; Dubowchik, G. M.; Roth, G. P.; Polson, C.; Fairchild, C. J. A new EGF-active polymeric pyridinium alkaloid from the sponge Callyspongia fibrosa. J. Org. Chem. 1993, 58, 5925-5930.
26. 2Ru:CHR olefin metathesis catalysts: an organometallic success story. Acc. Chem. Res. 2001, 34, 18-29.
27. Nosse, B.; Schall, A.; Jeong, B. W.; Reiser, O. Optimization of ring-closing metathesis: Inert gas sparging and microwave irradiation. Adv. Synth. Cat. 2005, 347, 1869-1874.
28. Inoue, S.; Mai, A.; Dyer, M. J.; Cohen, G. M. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2006, 66, 6785-6792.
29. de Ruijter, A. J. M.; ven Gennip, A. H.; Caron, H. N.; Kemp, S.; Kuilenburg, A. B. P. Histone deacetylases (HDACs). Characterization of the classical HDAC family. Biochem. J. 2003, 370, 737-749.
30. Gantt, S. L.; Gattis, S. G.; Fierke, C. A. Catalytic Activity and Inhibition of Human Histone Deacetylase 8 Is Dependent on the Identity of the Active Site Metal Ion. Biochemistry 2006, 45, 6170-6178.
31. Corminboeuf, C.; Hu, P.; Tuckerman, M. E.; Zhang, Y. Unexpected Deacetylation Mechanism Suggested by a Density Functional Theory QM/MM Study of Histone-Deacetylase-Like Protein. J. Am. Chem. Soc. 2006, 128, 4530-4531.
32. (a) Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Pavletich, N. P. Structures of a Histone Deacetylase Homologue Bound to the TSA and SAHA inhibitors. Nature 1999, 401, 188-193.
33. (b) Vannini, A.; Volpari, C.; Filocamo, G.; Casavola, E. C.; Brunetti, M.; Renzoni, D.; Chakravarty, P.; Paolini, C.; De Francesco, R.; Gallinari, P.; Steinkühler, C.; Di Marco, S. Crystal structure of a eukatyotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 15064-15069.
34. (c) Somoza, J. R.; Skene, R. J.; Katz, B. A.; Mol, C.; Ho, J. D.; Jennings, A. J.; Luong, C.; Arvai, A.; Buggy, J. J.; Chi, E.; Tang, J.; Sang, B.-C.; Verner, E.; Wynands, D. R.; Snell, G.; Navre, M.; Knuth, M. W.; Swanson, R. V.; McRee, D. E.; Tari, L. W. Structural Snapshots of Human HDAC8 Provide Insights Into the Class I Histone Deacetylase. Structure 2004, 12, 1325-1334.
35. Nielsen, T. K.; Hildmann, C.; Dickmanns, A.; Schwienhorst, A.; Ficner, R. Crystal structure of a Bacterial Class 2 Histone Deacetylase Homologue. J. Mol. Biol. 2005, 354, 107-120.
36. Hu, E.; Dul, E.; Sung, C.-M.; Chen, Z.; Kirkpatrick, R.; Zhang, G.-F.; Johanson, K.; Liu, R.; Lago, A.; Hofmann, G.; Macarron, R.; Perez, P.; Krawiec, J.; Winkler, J.; Jaye, M. Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases. J. Pharmacol. Exp. Ther. 2003, 307, 720-728.
37. Park, J.-H.; Jung, Y. J.; Kim, T. Y.; Kim, S. G.; Jong, H.-S.; Lee, J. W.; Kim, D.-K.; Lee, J.-S.; Kim, N. K.; Kim, T.-Y.; Bang, Y.-J. Class I Histone Deacetylase-Selective Novel Synthetic Inhibitors Potently Inhibit Human Tumor Proliferation. Clin. Cancer Res. 2004, 10, 5271-5281.
38. (a) Mai, A.; Massa, S.; Pezzi, R.; Rotili, D.; Loidl, P.; Brosch, G. Discovery of (Aryloxopropenyl)pyrrolyl Hydroxamides as Selective Inhibitors of Class IIa Histone Deacetylase Homologue HD1-A. J. Med. Chem. 2003, 46, 4826-4829.
39. (b) Mai, A.; Massa, S.; Valente, S.; Simeoni, S.; Ragno, R.; Bottoni, P.; Scatena, R.; Brosch, G. Aroylpyrrolyl hydroxyamides: influence of pyrrole C4-phenylacetyl substitution on histone deacetylase inhibition. ChemMedChem 2006, 1, 225-237.
40. (a) Grozinger, C. M.; Hassig, C. A.; Schreiber, S. L. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4868-4873.
41. (b) Fischle, W.; Kiermer, V.; Dequiedt, F.; Verdin, E. The emerging role of class II deacetylases. Biochem. Cell Biol. 2001, 79, 337-348.
42. (c) Bertos, N. R.; Wang, A. H.; Yang, X. Y. Class II Histone Deacetylases: Structure, Function and Regulation. Biochem. Cell Biol. 2001, 79, 243-252.
43. (a) Haggarty, S. J.; Koeller, K. M.; Grozinger, C. M.; Schreiber, S. L. Domain-selective Small-molecule Inhibitor of Histone Deacetylase 6 (HDAC-6)-mediated Tubulin Acetylation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 4389-4394.
44. (b) Suzuki, T.; Kouketsu, A.; Itoh, Y.; Hisakawa, S.; Maeda, T.; Yoshida, M.; Nakagawa, H.; Miyata, N. Highly Potent and Selective Histone Deacetylase 6 Inhibitors Designed Based on a Small-Molecule Substrate. J. Med. Chem. 2006, 49, 4809-4812.
45. Wang, D.-F.; Helquist, P.; Wiech, N. L.; Wiest, O. Toward Selective Histone Deacetylase Inhibitor Design: Homology Modeling, Docking Studies, and Molecular Dynamics Simulations of Human Class I Histone Deacetylase. J. Med. Chem. 2005, 48, 6936-6947.
46. Ibrahim, Y. A.; John, E. Efficient synthesis of 18-40 membered macrocyclic polyoxadiamides and polyoxatetraamides via ring closing metathesis. Tetrahedron Lett. 2006, 62, 1001-1014.
47. (a) Varghese, S.; Gupta, D.; Baran, T.; Jiemjit, A.; Gore, S. D.; Casero, R. A.; Woster, P. M. Alkyl-Substituted Polyhydroxamic Acids: A Novel Class of Targeted Histone Deacetylase Inhibitors. J. Med. Chem. 2005, 48, 6350-6365.
48. (b) Vu, Q. A.; Zhang, D.; Chroneos, Z. C.; Nelson, D. A. Polyamines inhibit the yeast histone deacetylase. FEBS Lett. 1987, 220, 79-83.
49. (a) Kapustin, G. V.; Fejér, G.; Gronlund, J. L.; McCafferty, D. G.; Seto, E.; Etzkorn, F. A. Phosphorus-Based SAHA Analogues as Histone Deacetylase Inhibitors. Org. Lett. 2003, 5, 3053-3056.
50. (b) Gurvich, N.; Tsygankova, O. M.; Meinkoth, J. L.; Klein, P. S. Histone Deacetylase Is a Target of Valproic Acid-Mediated Cellular Differentiation. Cancer Res. 2004, 64, 1079-1086.
51. (a) Mai, A.; Massa, A.; Rotili, D.; Simeoni, S.; Ragno, R.; Botta, G.; Nebbioso, A.; Miceli, M.; Altucci, L.; Brosch, G. Synthesis and Biological Properties of Novel, Uracil-Containing Histone Deacetylase Inhibitors. J. Med. Chem. 2006, 49, 6046-6056.
52. Altucci, L.; Rossin, A.; Raffelsberger, W.; Reitmair, A.; Chomienne, C.; Gronemeyer, H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat. Med. 2001, 7, 680-686.
53. Mai, A.; Massa, A.; Pezzi, R.; Simeoni, S.; Rotili, D.; Nebbioso, A.; Scognamigliio, A.; Altucci, L.; Loidl, P.; Brosch, G. Class II (IIa)-Selective Histone Deacetylase Inhibitors. 1. Synthesis and Biological Evaluation of Novel (Aryloxopropenyl)pyrrolyl Hydroxamides. J. Med. Chem. 2005, 48, 3344-3353.